MOTS-c vs SS-31: Which Is Better for Mitochondrial Health?
MOTS-c scores 6.5 and SS-31 6.0, and neither one has a human trial behind the use you want. MOTS-c takes blood sugar and body composition. SS-31 takes the…
- MOTS-c
- SS-31
Every intervention Outliyr has scored for eye health, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for eye health; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
24 of 73 evaluated interventions score 3.0+ out of 10 for eye health · 1 comparison
The main limitation behind Saffron's 7.2/10 eye vision score is that the evidence points to a plausible use case without proving a universal response. Piccardi et al. 2012 is the best anchor…
Read the Saffron report →Eye-vision earns 7.0/10 because Boyer 2024 found multiwavelength photobiomodulation improved visual-acuity outcomes in dry age-related macular degeneration. Rassi 2024 also supports a modest RCT signal for AMD. This is not permission to…
Read the Red Light Therapy report →The strongest eye and vision support argument for Astaxanthin is 7.0/10 because Liu 2024 reports 11 RCTs; 346 healthy participants; significant improvements reported across fatigue, cognition, and exercise-efficiency endpoints overall; endpoint details…
Read the Astaxanthin report →TB-500 (Thymosin Beta-4 Fragment) belongs in the 7.0/10 range for eye vision because the signal is conditional. Eye-vision has the best human signal because RGN-259 is full-length topical Tbeta4. Sosne 2015 found…
Read the TB-500 (Thymosin Beta-4 Fragment) report →Mechanistically, Taurine fits eye and vision support at 6.0/10 because Tzang 2024 reports 25 RCTs and 1024 participants; lower SBP, DBP, fasting blood glucose, and triglycerides; no significant adverse-effect excess. Tzang 2024…
Read the Taurine report →Dry-eye relief earns 6.0/10, driven by the topical drop, not the oral capsule. Yang 2021 pooled 19 RCTs (2,078 eyes) and found hyaluronic acid eye drops significantly improved tear production versus non-HA…
Read the Hyaluronic Acid report →Metformin receives a 5.5/10 rating for the eye-vision use case, reflecting an observational association with reduced age-related macular degeneration odds reported in a 2025 cohort study Huh 2025. The evidence tier is…
Read the Metformin report →Glycine eye vision earns 5.0/10 because Soh 2024 anchors the most relevant signal. Glycine fits eye vision because glycine participates in sleep signaling, glutathione, collagen, methylation, and nervous-system balance, depending on the…
Read the Glycine report →Eye and vision use is the only Tβ4 indication with a Phase 3 primary-endpoint win in humans. The SEER-1 Phase 3 trial in neurotrophic keratopathy hit on complete epithelial defect healing and…
Read the Thymosin Beta-4 (Tβ4) report →For eye vision, SS-31 (Elamipretide) earns 5.0/10 because the evidence points to a plausible use case without proving a universal response. Ehlers JP et al. 2024 is the best anchor here because…
Read the SS-31 (Elamipretide) report →Vision is mixed for HBOT. Central retinal artery occlusion appears on some indication lists, but transient myopia and cataract concerns are common adverse-event issues. Zhang 2023 documents adverse-event rates including vision changes…
Read the Hyperbaric Oxygen Therapy report →No direct eye or vision evidence was verified for EAA supplementation. Score remains below neutral.
Read the Essential Amino Acids report →Allergic eye symptom data come from EMIQ and phytosome trials. Yamada 2022 randomized 66 adults to 200 mg/day quercetin phytosome for 4 weeks, with improvements in eye itching, sneezing, nasal discharge, and…
Read the Quercetin report →No direct eye or vision evidence for Ca-AKG. Avoid borrowing from unrelated photobiomodulation or mitochondrial eye studies.
Read the Ca-AKG (Calcium Alpha-Ketoglutarate) report →Eye score is limited by diabetic retinopathy worsening concerns and the Hathaway 2024 NAION association, even though causality remains unresolved.
Read the Semaglutide report →INSUFFICIENT_EVIDENCE for human vision benefit outside disease-specific research, with no practical healthy-user signal.
Read the Rapamycin report →Ocular injury risk at high magnitudes has been noted in the broader vibration literature. Therapeutic ranges are safer, but retinal risk remains a relative contraindication.
Read the Whole-Body Vibration report →Russian clinical and cell-literature interest in retinal tissues gives Epitalon a stronger eye-vision signal than most categories. Khavinson 2003 reported peptide effects on retinal and pigmented epithelial cell proliferative activity, but v1.0…
Read the Epitalon report →Early preclinical work on ocular oxidative stress is interesting, but there is no human eye-outcome trial. Mechanistic and preliminary only.
Read the Ergothioneine report →Tirzepatide improves glycemia, which can support diabetic eye risk over time. Rapid glucose improvement with incretin therapies can complicate retinopathy monitoring in some diabetes contexts. There is no tirzepatide eye vision enhancement…
Read the Tirzepatide report →Fitness and vascular health may support retinal health indirectly, especially through blood pressure and glucose control. Zone 2 is not a vision protocol and should not replace ophthalmology care for retinal disease.
Read the Zone 2 Cardio report →Eye and vision support is mechanistic only here. Vitamin C is concentrated in the eye and is one of the antioxidants in the AREDS2 formulation studied for age-related macular degeneration, but in…
Read the Vitamin C (Ascorbic Acid) report →Autophagy is relevant to retinal aging, but no verified human spermidine outcome trial supports an eye-specific claim.
Read the Spermidine report →Russian clinical use includes optic-nerve indications, but accessible verified evidence remains limited and does not reach Western ophthalmology guideline strength.
Read the Semax report →Nothing matches those filters.
Head-to-head reports and category rankings that name a winner on this use case.
MOTS-c scores 6.5 and SS-31 6.0, and neither one has a human trial behind the use you want. MOTS-c takes blood sugar and body composition. SS-31 takes the…
Saffron, at 7.2 out of 10 for eye health. The main limitation behind Saffron's 7.2/10 eye vision score is that the evidence points to a plausible use case without proving a universal response.
Of the top-scoring options, Glycine is the least expensive at about $2 a month, scoring 5.0 out of 10 for eye health.
24 of the 73 interventions evaluated for eye health score 3.0 out of 10 or better, which is the cut-off for appearing on this page.